Sickle Hemoglobinopathy in West Bengal, India: Review of Literature and Future Direction

Main Article Content

Prakas Kumar Mandal


Sickle cell disease (SCD) was the first example of a ‘molecular disease’. SCD patients experience considerable morbidity from both acute and chronic sequelae; most severe cases can be fatal within the first few years of life without effective treatment or with sub-optimal treatment. In India, reported sickle-cell allele frequency is 10% spanned central India. West Bengal is the first state in India which had launched the State Thalassaemia Control Programme (STCP) for prevention of thalassemia since 2008. The present systematic review was made to know the community load of sickle hemoglobinopathy in West Bengal, an eastern state in India. Among all, as per the recently published, largest study screened for hemoglobinopathies over a period of 10 years, the estimated community load of sickle hemoglobinopathy in West Bengal would be sickle cell trait/carrier (703,010 cases; 0.77%), HbS beta thalassemia (45,650 cases; 0.05%) and SCD (36,520 cases; 0.04%). The National Health Mission, Government of India in 2016 have published the guidelines for ‘prevention and control of hemoglobinopathies in India’. Data from many functioning thalassemia control units (TCUs) in West Bengal are not yet published; therefore not available for the current review. All the TCUs in West Bengal should publish their data to help the Government in planning comprehensive management of SCD including other thalassemia cases.

Sickle hemoglobinopathy, West Bengal, iiterature review, burden, future direction.

Article Details

How to Cite
Mandal, P. K. (2020). Sickle Hemoglobinopathy in West Bengal, India: Review of Literature and Future Direction. Asian Hematology Research Journal, 3(4), 49-57. Retrieved from
Review Article


Pauling L, Itano H, Singer SJ, Wells IC. Sickle cell anemia: A molecular disease. Science. 1949;110:543–8.

Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anemia haemoglobin. Nature. 1956;178:792–4.

Odièvre MH, Verger E, Silva-Pinto AC, Elion J. Pathophysiological insights in sickle cell disease. Indian J Med Res. 2011;134(4):532-537.

Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017; 376(16):1561-1573. DOI:10.1056/NEJMra1510865

Steinberg MH, Steinberg MH, Forget BG, Higgs DR, Nagel RL. Compound heterozygous and other sickle hemoglobinopathies. Disorders of hemoglobin: Genetics, pathophysiology, and clinical management. 1st ed. Cambridge, UK: Cambridge University Press. 2001;786–810.

Kinney TR, Ware RE, Steinberg MH, Hebbel RP, Mohandas N, Embury SH,. Compound heterozygous states. Sickle cell disease: basic principles and clinical practice. 1st Ed. New York: Raven Press Ltd. 1994;437–51.

Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59(2):386-390. DOI:10.1002/pbc.24175

Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistics model-based map and population estimates. Lancet. 2013;381:142–5.

Odame I. Developing a Global Agenda for sickle cell disease. Report of an International Symposium and Workshop in Cotonou, Republic of Benin. Am J Prev Med. 2010;38(4S):S571–S575.

Silva-Pinto AC, de Queiroz MCA, Zamaro PJA , Arruda M and Dos Santos HP. The neonatal screening program in Brazil, focus on sickle cell disease (SCD). Int J Neonatal Screen. 2019;5(11):1-7.

Nnodu OE, Sopekan A, Nnebe-Agumadu U, et al. Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: A feasibility study. Lancet Haematol. 2020;7:534–40.

Lehmann H, Cutbush M. Sickle-cell trait in Southern India. Br Med J. 1952;1(4755): 404–405. DOI: 10.1136/bmj.1.4755.404

Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–51. DOI:

Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S & Piel FB. The spatial epidemiology of sickle cell anaemia in India. Sci Rep. 2018;8:17685 | DOI:10.1038/s41598-018-36077-w

Colah R, Mukherjee M & Ghosh K. Sickle cell disease in India. Curr Opin Hematol. 2014;21:215–23. https://DOI:org/10.1097/moh.0000000000000029 (2014).

Balgir RS, Sharma SK. Distribution of sickle cell haemoglobin in India. Indian J Hematol. 1988;6:1–14.

Serjeant GR, Ghosh K, Patel J. Sickle cell disease in India: A perspective. Indian J Med Res. 2016;143(1):21–24. DOI: 10.4103/0971-5916.178582

Odame I and Jain D. Sickle cell disease: Progress made & challenges ahead. Indian J Med Res. 2020;151(6):505– 508. DOI: 10.4103/ijmr.IJMR_2064_20.

Chaudhuri S, Ghosh J, Mukherjee B, Roychoudhury AK. Study of blood groups and haemoglobin variants among the Santal tribe in Midnapore district of West Bengal, India. Am J Phys Anthropol. 1967;26(3):307-311. DOI:10.1002/ajpa.1330260305

Bhattacharyya PK, Ghosh TN, Basu AK, Chakraborty R. The sickle cell trait in the Santhals of Ajodhya hills of Purulia district, West Bengal. Trans R Soc Trop Med Hyg. 1981;75(4):615-616. DOI:10.1016/0035-9203(81)90228-5

Mohanti D, Colah R, Gorakshakar A. Jay Vigyan S and T mission project on community control of thalassaemia syndromes –awareness, screening, genetic counseling and prevention. A national multicentric task force study of the Indian council of Medical Research (ICMR), New Delhi, 2008 (ISBN-81-901853-0-1) (

Mohanty D, Colah RB, Gorakshakar AC, et al. Prevalence of b-thalassemia and other haemoglobinopathies in six cities in India: A multicentre study. J Community Genet. 2013;4:33-42. DOI:10.1007/s12687-012-0114-0

Choudhuri S, Sen A, Ghosh MK, Misra S & Bhattacharyya M. Effectiveness of Prenatal Screening for Hemoglobinopathies in a developing country. Hemoglobin. 2014;39:380- 383. DOI:

Jain BB, Roy RN, Ghosh S, Ghosh T, et al. Screening for thalassemia and other hemoglobinopathies in a tertiary care hospital of West Bengal: Implications for population screening. Indian J Public Health. 2012;56:297-300.

Dolai TK, Dutta S, Bhattacharyya M and Ghosh MK. Prevalence of hemoglobinopathies in rural Bengal, India. Hemoglobin. 2012;36(1):57–63. DOI: 10.3109/03630269.2011.621007

Mandal PK, Maji SK, Dolai TK. Present scenario of hemoglobinopathies in West Bengal, India: An analysis of a large population. Int J Med Public Health. 2014;4(4):496-499.

Chattopadhyay P, Kundu S, Saha TN, Chatterjee K. Study of hemoglobinopathies at a referral laboratory in a western district of West Bengal among the antenatal women and premarital men and women: A 2 years study. International Journal of Contemporary Medical Research. 2019; 6(6):F24-F27. DOI:

Maji SK, Dolai TK, Pradhan S, Maity A, Mandal S, Mondal T, Manna S & Mandal PK. Implications of population screening for Thalassemias and Hemoglobinopathies in Rural Areas of West Bengal, India: Report of a 10-year study of 287,258 Cases, Hemoglobin; 15 Oct 2020. DOI: 10.1080/03630269.2020.1831530

Ghosh N, Chakrabarti I, Chakraborty M, et al. A community based pilot study on prevalence of hemoglobinopathies among the antenatal women in a rural area of Darjeeling district, West Bengal. Int J Med Public Health. 2013;3:107-10.

Goswami BK, Pramanik R, Chakrabarty S, et al. Spectrum of hemoglobin variants in the population of northern region of West Bengal: An ethnogenetic proposition. J Fam Med Primary Care. 2014;3:219- 23.

Mukhopadhyay D, Saha K, Sengupta M, et al. Spectrum of hemoglobinopathies in West Bengal, India: A CE-HPLC Study on 10407 Subjects. Indian J Hematol Blood Transfus. 2015;31(1):98–103. DOI 10.1007/s12288-014-0373-5.

Mondal SK, Mandal S. Prevalence of thalassemia and hemoglobinopathy in eastern India: A 10-year high-performance liquid chromatography study of 119,336 cases. Asian J Transfus Sci 2016;10:105-10

Chakrabarti S, Mandal K, Pathak S, Patra A, & Pal S. Haemoglobinopathies among the tribal and non-tribal antenatal mothers in a tertiary care hospital of rural West Bengal, India. Bangladesh Journal of Medical Science. 2016;15(1):90-94. DOI:https://doi:org/10.3329/bjms.v15i1.18647

Naskar S, Biswas G, Paul SR, et al. Prevalence of Thalassaemia and Other Hemoglobinopathies. In a Northern district of West Bengal, India. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS). 2015;14:43-45. DOI:10.9790/0853-14424345.

Bhattacharyya KK, Chatterjee T & Mondal UB. A comprehensive screening program for beta thalassemia and other hemoglobinopathies in the Hooghly district of West Bengal, India, dealing with 21,137 cases. Hemoglobin. 2016;40:6,396-399. DOI: 10.1080/03630269.2016.1259169

Chatterjee T, Chakravarty A, Chakravarty S. Population Screening and Prevention Strategies for Thalassemias and other Hemoglobinopathies of Eastern India: Experience of 18,166 cases. Hemoglobin. 2015;39(6):384-388. DOI:10.3109/03630269.2015.1068799.

Demographic Features. Public Health in West Bengal –Current Status and Ongoing Interventions.

Ray R, Roy S, Sarkar A, et al. Near extinction of HbS among the tribes in Bengal: An effect of epistasis? Blood. 2017;130:4777. https://DOI:org/10.1182/blood.V130.Suppl_1.4777.4777

Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): A trial for children with sickle cell anemia. Blood. 2017;130:2585–2593. DOI: 10.1182/blood-2017-06-788935

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With transfusions changing to hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661–70.

U.S. national library of medicine. Sickle cell disease - stroke prevention in Nigeria trial (SPIN). Identifier: NCT01801423.

Jain D, Ganesan K, Sahota S, Darbari DS, Krishnamurti L, Kirkham FJ. Transcranial doppler screening in children with sickle cell anemia is feasible in central India and reveals high risk of stroke. Blood. 2019; 134(1):2279.

McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, et al. Hydroxyurea therapy for children with sickle cell anemia in Sub-Saharan Africa: Rationale and design of the REACH trial. Pediatr Blood Cancer. 2016;63:98–104

Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020;11(435):1- 15. DOI: 10.3389/fphys.2020.00435.

Okpala IE. Sickle cell crisis. In, practical management of haemoglobinopathies, Okpala IE (Ed.), Blackwell Publishing. 2004;63–71.

Aygun B, Odame I. A global perspective on sickle cell disease. Pediatr Blood Cancer. 2012;59(2):386-390. DOI:10.1002/pbc.24175

Ghosh K, Colah R, Manglani M, et al. Guidelines for screening, diagnosis and management of hemoglobinopathies. Indian J Hum Genet. 2014;20(2):101- 119. DOI:10.4103/0971-6866.142841.

EuroBloodNet. Inaugural meeting of the Global Alliance of Sickle Cell Disease Organizations (GASCDO); 2020. Available:,Network%20of%20SCD%20Patients%20Organizations .

National Health Mission. Guidelines on hemoglobinopathies in India: Prevention and control of hemoglobinopathies in India - thalassemias, sickle cell disease and other variant hemoglobins. New Delhi: Ministry of health & family welfare, government of India; 2016.